Over the past decade, cannabis has shifted from taboo to a regulated global industry, with expanding legalization, medical adoption, and economic impact. Yet in 2026, early “Green Rush” expectations have given way to a more complex reality shaped by bureaucracy, uneven policies, and ongoing cultural and political debate.
Riding the wave of social media trends these past few months—that nostalgic look back at pictures and anecdotes from 2016 to 2026—a question arises: what’s happened in the cannabis world over the last 10 years? Have there been significant changes? Has the needle shifted? Do prejudices still persist? Has any country taken a leap backward or forward? Does society continue to demand change? Does the health sector still require solutions? Does leisure continue to exert pressure from its entrenched position?
Broadly speaking, thanks to the growing democratization of the conversation, the cannabis landscape is undergoing a profound transformation and gaining momentum: little by little, it is ceasing to be a taboo subject. There’s still a long way to go, but the ground has been shifting. Likewise, cannabis gradually shed its largely criminalized image to become—joint by joint, plant by plant, medicine by medicine—a regulated global industry, and even a—somewhat—standardized medical resource.
Where things stood in 2016
Barely three years had passed since Uruguay legalized recreational weed in December 2013, becoming the first country in the world to do so. That law allowed home cultivation in August 2014. And by 2016, the world was already watching the Uruguayan experiment with some curiosity.
Around that time, some US states like Colorado, Washington, Oregon, and Alaska had legalized adult use. And at the end of 2016, California, Massachusetts, Maine, and Nevada voted in favor of recreational legalization, which ultimately changed the game given California’s economic weight.
Key milestones — 2013 to 2026
2013
Uruguay legalizes recreational cannabis
First country in the world to do so.
2016
California, Massachusetts, Maine and Nevada vote yes
California’s economic weight changes the game.
2018
Canada legalizes nationally
First G7 nation to legalize adult-use cannabis federally.
2020
UN removes cannabis from Schedule IV
Recognizes therapeutic value. Removed from “most dangerous substances” list.
2024
Germany legalizes
Europe’s largest economy joins the movement.
2026
Czech Republic joins, US passes 24 states
60+ countries now have medicinal cannabis programs.
The Green Rush that wasn’t — and what came after
In 2016, there was widespread talk of a “Green Rush,” with investors expecting quick profits and few restrictions, primarily in the United States and much of Europe. That “Green Rush” fizzled out: those expectations never fully materialized. Or not entirely. Or not in that way.
Today, the market is much more professional and, it must be said, more rigorous. This makes sense: the ecosystem has been shaken up, some bubbles have burst, and the industry has become more professional. Today, the industry is estimated to contribute approximately US$149 billion to the global economy.
$149B
Estimated global economic contribution of the cannabis industry in 2026
Equivalent to the entire GDP of Ecuador, Panama or Uruguay
60+
Countries with active medicinal cannabis programs
Up from a handful in 2016
24+
US states that have regulated cannabis
Federal law remains unchanged
To put this into perspective: that $149 billion figure is the entire GDP of countries like Ecuador, Panama, or Uruguay, and it’s almost the same as the hotel and tourist accommodation sector in the United States, according to the Bureau of Economic Analysis. In this context, countries like Thailand and Canada have consolidated their position as exporting powerhouses, sending hundreds of tons annually to European markets.
The regulatory landscape in 2026
Ideas about “legalizing or prohibiting” continue to circulate in society, politics, the media, and social networks. The debate remains open and without conclusive arguments. Various regulatory models are now active simultaneously: US states with retail sales and substantial tax collection; Germany and Spain with non-profit collective cultivation—despite their notable drawbacks; the Czech Republic and Luxembourg allowing self-cultivation and possession, focusing on personal freedom and decriminalization; and France’s strictly medicinal model, with exclusive dispensing in pharmacies and hospitals.
Active regulatory models in 2026
1
Retail sales with tax collection
Most US states. Commercial dispensaries, regulated market, significant tax revenue.
2
Non-profit collective cultivation
Germany, Spain. Cannabis social clubs and associations. Notable implementation challenges.
3
Self-cultivation and possession
Czech Republic, Luxembourg. Focused on personal freedom and decriminalization over commercial access.
4
Strictly medicinal
France. Exclusive dispensing through pharmacies and hospitals. No recreational access.
And although cannabis acceptance is growing, the International Narcotics Control Board (INCB) continues to express its “concern” about the increase in use and the decline in risk perception. This situation ultimately led many countries to favor stricter medicalization and pharmaceutical traceability instead of seeking openness (total or partial).
A more orderly garden — with questions still open
Thus, 2026 finds us with a—somewhat—more orderly garden. Without the naiveté of those early times, users, patients, and businesses continue to navigate a labyrinth of labels, genetics, and legislation. Looking ahead, is a victory for individual freedoms on the horizon, or are we simply witnessing the domestication of the plant? Does state bureaucracy stifle or collaborate? Does the mystique fade without resistance? Can health be confined to a court case file? In 2027, the next trend will offer different answers to these questions that today, right now, at this very moment, still linger in wisps of smoke.
